Systemic Lupus Erythematosus

Prioritize immediate assessment for kidney injury, neuropsychiatric disease, severe cytopenias, thrombosis, pregnancy complications, and cardiopulmonary involvement. Renal and neuropsychiatric manifestations contribute substantially to SLE morbidity and mortality, while immunosuppressive therapy further increases infection risk. Nature+1NaturePediatric SLE—towards a comprehensive management plan | Nature Reviews RheumatologyNatureSystemic lupus erythematosus | Nature Reviews Disease Primers

In a patient with suspected active systemic disease, obtain CBC with differential and platelets, serum creatinine, urinalysis with sediment, quantitative proteinuria, serum albumin, complement levels, anti-dsDNA, and targeted testing for antiphospholipid antibodies when thrombosis or obstetric morbidity is present. Low complement, anti-dsDNA, anti-Sm, and antiphospholipid antibodies are diagnostic aids; anti-dsDNA and anti-Sm are relatively specific but insensitive, whereas ANA is sensitive but nonspecific. BMJ+1BMJUpdate οn the diagnosis and management of systemic lupus erythematosusBMJCell-bound complement activation products in SLE

New hypertension, edema, substantial proteinuria, lipid casts, fat oval bodies, abnormal urinary sediment, or loss of kidney function should shift management toward possible lupus nephritis rather than attribution to nonspecific SLE activity. A pregnancy-associated renal presentation also requires a competing assessment for preeclampsia, as severe hypertension and proteinuria can occur in that setting. BMJ+1BMJInteractive case study workshopsScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

The diagnosis of SLE is clinical and supported by laboratory evidence of immune reactivity or inflammatory organ injury. The 2019 EULAR/ACR criteria have favorable sensitivity and specificity among contemporary classification systems, but they are classification criteria rather than diagnostic criteria. BMJ+1BMJUpdate οn the diagnosis and management of systemic lupus erythematosusBMJUpdate οn the diagnosis and management of systemic ...

ANA positivity is the EULAR/ACR 2019 entry criterion, but a negative ANA should not automatically exclude SLE when the phenotype is persuasive. In an incident cohort, 18 of 737 patients (2.4%) were ANA-negative at diagnosis; another cohort included ANA-negative patients with biopsy-proven class III, IV, and V lupus nephritis. BMJ+1BMJSensitivity of classification criteria from time of diagnosis in an incident systemic lupus erythematosus cohort: a population-based study from Norway | RMD OpenBMJPerformance of the proposed ACR–EULAR classification ...

Interpret ANA by assay context and pretest probability. ANA is common in SLE but may occur in healthy individuals and other disorders, producing high sensitivity but low specificity; assay differences can also change apparent positivity. Anti-dsDNA and anti-Sm increase diagnostic specificity but do not have sufficient sensitivity to rule out disease. BMJBMJCell-bound complement activation products in SLE

When patients do not meet a classification threshold but have a compatible phenotype, document the objective clinical and immunologic evidence, reassess longitudinally, and exclude competing connective-tissue, infectious, thrombotic, drug-related, and organ-specific diagnoses. For ANA-negative suspected SLE, low complement and/or antiphospholipid antibodies may provide an alternative immunologic entry point in a diagnostic algorithm. BMJ+1BMJUpdate οn the diagnosis and management of systemic lupus erythematosusBMJUpdate οn the diagnosis and management of systemic ...

Use hydroxychloroquine for essentially all patients with SLE unless contraindicated or not tolerated. The EULAR target is 5 mg/kg/day or less using real body weight, individualized against the competing risks of flare and retinal toxicity. ScienceDirectScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Use systemic glucocorticoids as bridging treatment during active disease, not as a default chronic maintenance strategy. For maintenance, minimize prednisone-equivalent exposure to 5 mg/day or less and withdraw when possible; prompt use of steroid-sparing immunosuppressive drugs and/or biologic agents facilitates tapering. ScienceDirectScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

For nonrenal inflammatory disease requiring escalation beyond hydroxychloroquine, consider methotrexate, azathioprine, or mycophenolate, and consider belimumab or anifrolumab when disease remains active or steroid tapering is not achievable. Choice should be driven by the dominant disease domain, reproductive considerations, prior immunosuppressant exposure, infection risk, and the objective need to reduce glucocorticoid exposure. ScienceDirectScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Reserve cyclophosphamide for organ-threatening disease and consider rituximab for refractory disease. This distinction matters because cyclophosphamide is positioned for high-severity inflammatory organ injury, whereas rituximab is an option when standard approaches have not achieved control. ScienceDirectScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Active lupus nephritis should be considered when SLE is accompanied by proteinuria, urinary sediment abnormalities, edema, hypertension, hypoalbuminemia, or kidney dysfunction. Quantify proteinuria and assess sediment rather than relying on dipstick results alone; nephrotic-range proteinuria with low albumin and lipid casts or fat oval bodies identifies a nephrotic pattern that warrants focused renal evaluation. BMJBMJInteractive case study workshops

For active lupus nephritis, use glucocorticoids plus mycophenolate or low-dose intravenous cyclophosphamide as anchor treatment. Consider adding belimumab or a calcineurin inhibitor, specifically voclosporin or tacrolimus, to the anchor regimen. ScienceDirectScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Do not classify all proteinuria in pregnancy as active nephritis. Severe hypertension, weight gain, and proteinuria arising late in pregnancy may represent preeclampsia; persistent postpartum proteinuria requires reassessment for an underlying renal process rather than assuming the pregnancy complication fully explains ongoing urinary abnormalities. BMJBMJInteractive case study workshops

Follow renal response with serial quantitative proteinuria, serum creatinine, urine sediment, serum albumin when nephrotic features are present, blood pressure, and concurrent SLE activity measures. Escalate the diagnostic discussion when renal findings and systemic immune activity diverge, because ANA status and even conventional serologies do not reliably exclude biopsy-proven lupus nephritis. BMJ+2BMJPerformance of the proposed ACR–EULAR classification ...BMJInteractive case study workshopsScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

At follow-up, repeat disease- and organ-specific measures that were abnormal at presentation: CBC for cytopenias, creatinine and quantitative proteinuria with urine sediment for renal disease, complement and anti-dsDNA as adjunctive immune activity markers, and focused cardiopulmonary or neurologic testing when those organs are involved. This approach separates clinical activity from damage and permits glucocorticoid tapering only when objective control is sustained. BMJ+1BMJUpdate οn the diagnosis and management of systemic lupus erythematosusScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Maintain hydroxychloroquine within the individualized weight-based target and revisit adherence, toxicity, and flare history when disease appears active. Lower hydroxychloroquine blood concentrations have been associated with exacerbations, and long-term hydroxychloroquine exposure requires attention to retinal and cardiac toxicity. Nature+1NatureEffect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus | Scientific ReportsScienceDirectEULAR recommendations for the management of systemic lupus erythematosus: 2023 update

For patients with aPL and prior thrombosis or pregnancy morbidity, manage the patient as possible APS rather than as isolated SLE seropositivity. Secondary thrombosis prevention and modification of cardiovascular risk factors are important because subsequent damage worsens health-related quality of life. Wolters Kluwer+1Wolters Kluwer22nd PANLAR Congress: Miami, FL, August 12-15 2020ScienceDirectAntiphospholipid Syndrome - an overview

Include structured nonpharmacologic care rather than treating pharmacotherapy as the entire intervention. EULAR emphasizes holistic, multidisciplinary, patient-involved, individualized strategies to improve quality of care and health-related quality of life in SLE. BMJBMJEULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis | Annals of the Rheumatic Diseases